Drugs / AT02
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05521022 | Sep 2022 → Mar 2025 | amyloidosis | Attralus, Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05951049 | Sep 2023 → Sep 2026 overdue | amyloidosis | Attralus, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00788229 | Nov 2008 → Aug 2009 | dry eye syndrome | Dhp Korea Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-08-12 | Attralus, Inc. | Regulatory Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis attralus.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for zamubafusp alfa (AT-02) for the treatment of light chain (AL)-associated amyloidosis, a rare, progressive, debilitating, and often fatal condition. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-12 | Attralus, Inc. | Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis attralus.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT-02 | “AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.” NCT05951049 ↗ |
| Modality | Monoclonal antibody | “full-length, humanized, recombinant immunoglobulin 1 (IgG1)-like glycoprotein monoclonal antibody (mAb)” NCT05521022 ↗ |
| Route | Other | “eye drop for 12 weeks” NCT00788229 ↗ |